Isotretinoin syndrome

Isotretinoin syndrome, also known as isotretinoin embryopathy or retinoic acid embryopathy, is a pattern of birth defects caused by prenatal exposure to isotretinoin (13-cis-retinoic acid), a medication commonly prescribed for severe cystic acne. Isotretinoin is a potent teratogen, meaning it can cause serious harm to a developing fetus when taken during pregnancy, particularly during the first trimester. This condition is not inherited but results from the direct toxic effects of the drug on embryonic development. The syndrome affects multiple organ systems. Key clinical features include craniofacial abnormalities such as microtia (small or absent ears), anotia, micrognathia (small jaw), and cleft palate. Central nervous system malformations are common and may include hydrocephalus, microcephaly, and intellectual disability. Cardiovascular defects, particularly conotruncal heart malformations (such as transposition of the great vessels, tetralogy of Fallot, and ventricular septal defects), are frequently observed. Thymic abnormalities, including thymic aplasia or hypoplasia, may also occur, potentially leading to immune deficiency. There is no cure for isotretinoin syndrome, and management is supportive and symptom-specific. Treatment may involve surgical correction of craniofacial and cardiac defects, early intervention programs for developmental delays, and ongoing monitoring of neurological and immune function. Prevention is the most critical strategy: strict pregnancy prevention programs (such as iPLEDGE in the United States) have been implemented to ensure that women of childbearing potential do not become pregnant while taking isotretinoin. Women must use effective contraception and undergo regular pregnancy testing before, during, and after treatment with the drug.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Isotretinoin syndrome